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Objective: Although a few consistent osteoarthritis (OA) susceptibility genes have been identiﬁed, little is
known on OA progression. Since OA progression is clinically the most relevant phenotype, we investigate
the association between asporin (ASPN), bone morphogenetic protein 5 (BMP5) and growth differenti-
ation factor 5 (GDF5) polymorphisms and progression of hand OA.
Methods: Single-nucleotide polymorphisms (SNPs) ASPN rs13301537, BMP5 rs373444 and GDF5 rs143383
were genotyped in 251 hand OA patients from the Genetics osteoARthritis and Progression (GARP) study
and 725 controls. In a caseecontrol comparison we assessed the association between these SNPs and
radiographic progression of hand OA over 6 years, which was based on change in osteophytes or joint
space narrowing (JSN), above the smallest detectable change. SNPs with suggestive evidence for asso-
ciation were further analysed for their effect on progression over 2 years, and for the mean change in
osteophytes and JSN.
Results: The minor allele of ASPN SNP rs13301537 was associated with hand OA progression over 6 years
(odds ratio (OR) (95% CI) 1.49 (1.06e2.07); P ¼ 0.020). The mean change in osteophytes and JSN was
higher in carriers of the minor allele compared to homozygous carriers of the common allele with mean
difference of 0.73 (95% CI e 0.07e1.56; P ¼ 0.073) and 0.82 (95% CI 0.12e1.52; P ¼ 0.022), respectively.
An association with similar effect size was found between ASPN SNP rs13301537 and 2-year progression,
and the mean change in osteophytes and JSN was signiﬁcantly higher in homozygotes.
Conclusion: ASPN is associated with hand OA progression. This gives insight in the pathogenesis of hand
OA progression and identiﬁed a potential target for therapeutic approaches.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a common joint disorder characterised by
degradation of cartilage and changes in subchondral bone and
a leading cause of disability1. It is therefore a burden not only for the
individual but also for society. OA is a multifactorial disease
involving both genetic and environmental factors. The hand is the
most frequently involved joint site2.
The role of genetic factors in inﬂuencing OA susceptibility is well
documented3,4. However, very few studies assessed the role of OA
susceptibility genes in the disease course. One of the difﬁculties in
studying OA progression is its gradual and slow pace. Identiﬁcation. Bijsterbosch, Department of
1-R, P.O. Box 9600, 2300 RC
-71-5266752.
sch).
s Research Society International. Pof genes associated with OA progression will expand our knowl-
edge on the pathophysiological pathways involved in this process.
This can contribute to the development of much desired new
treatments and to the identiﬁcation of patients at high risk for
progression. Earlier we reported the presence of familial aggrega-
tion in OA progression in a relatively small number of sibling pairs
over a period of 2 years indicating a role for genetics in OA
progression5.
It is generally accepted that the genetic architecture of OA onset
is complex and is expected to be modulated by many genes with
small effects. Genetic studies have provided a few consistent signals
with relevant functional follow-up. Among these genes are growth
differentiation factor 5 (GDF5)6,7, bone morphogenetic protein 5
(BMP5)8,9 and asporin (ASPN)10,11, all involved in transforming
growth factor b (TGF-b) signalling. GDF5 and BMP5 have been
shown to be essential in the maintenance and repair of synovial
joints as well as chondrogenesis and chondrocyte proliferation. Theublished by Elsevier Ltd. All rights reserved.
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consistently associated with various subtypes of OA and with
reduced activity in chondrogenic cells. SNP rs3734444 was shown
to mark allelic imbalanced expression of BMP5. ASPN belongs to
a family of small leucine-rich proteoglycans (SLRPs), which com-
pose a major non-collagen component of the extra cellular matrix.
The aspartic acid repeat (D) 14 allele was associated with an
increased risk of knee OA, whereas the D13 allelemay be protective.
Interestingly, functional studies showed that ASPN binds to TGF-
b and thereby inhibits its function10,12. Because these genes are
involved in chondrogenesis and chondrocyte proliferation, we
expect them not only be involved in the onset of OA but also in the
further evolution of the disease.
Therefore we investigated the association between single-
nucleotide polymorphisms (SNPs) within GDF5, BMP5 and ASPN
and radiographic hand OA progression in patients from the Ge-
netics osteoARthritis and Progression (GARP) study that were fol-
lowed for 6 years. SNPs with suggestive evidence for association
were further investigated for associationwith hand OA progression
over 2 years, reﬂecting fast progression. We assessed hand OA since
it has by far the highest prevalence in our study population.
Patients and methods
Study design and selection of patients
The GARP study is a cohort study aimed at identifying de-
terminants of OA susceptibility and progression, comprising 192
Caucasian sibling pairs with symptomatic OA at multiple sites in
the hands or in at least two of the following joint sites: hand, knee,
hip, or spine. Patients were assessed at baseline and after 6 years.
Additionally, sibling pairs with at least one subject with symp-
tomatic hip or knee OA were evaluated after 2 years. This group
only partly comprises the same patients evaluated after 6 years.
Details on the recruitment and selection and on both follow-up
periods have been published elsewhere13e15. The GARP study was
approved by the Medical Ethics Committee.
Patients were eligible for the present study if they had radio-
graphic hand OA at baseline deﬁned as the presence of a Kellgrene
Lawrence score16 of2 in at least two interphalangeal joints or ﬁrst
carpometacarpal (CMC-1) joints. To allow for caseecontrol com-
parison we included partners of the offspring in the Leiden lon-
gevity study as random control population (N ¼ 739)17.
Radiographic outcome
Standardised radiographs of the hands (dorsalevolar) were
obtained at baseline and after both follow-up periods by a single
radiographer. Radiographs were scored in pairs (baseline-2 year,
baseline-6 year) blinded for patient characteristics by consensus
opinion of two experienced readers using the OARSI atlas18.
Osteophytes and joint space narrowing (JSN) were graded 0e3 in
the distal interphalangeal (DIP) joints, proximal interphalangeal
(PIP) joints, ﬁrst interphalangeal joints of the thumb (IP-1), CMC-1
joints, metacarpophalangeal (MCP) joints and scaphotrapezio-
trapezoidal (STT) joints, total scores ranging from 0 to 96.
Intra-reader reproducibility based on repeated reading of a 10%
random selection of radiographs was high with intra-class corre-
lation coefﬁcients (ICCs) for the 2-year and 6-year period, respec-
tively, of 0.98 and 0.92 for osteophytes and 0.94 and 0.87 for JSN.
Radiographic progression was deﬁned as a change in osteophytes
or JSN above the smallest detectable change (SDC), reﬂecting
change above measurement error19. Over 2 years the SDC was 0.9
and 0.8 for osteophytes and JSN, respectively. The SDC over 6 years
was 1.3 for osteophytes and 1.5 for JSN.SNP selection and genotyping
Because of our relatively small sample of hand OA patients we
could only investigate a limited number of SNPs. The selection
was based on SNPs that have shown consistent association with
OA susceptibility within one pathway, the TGF-b superfamily, as
explained in the Introduction. The three SNPs are: GDF5 rs143383,
BMP5 rs3734444 and ASPN rs13301537.
These genetic variants were genotyped using genomic DNA
extracted from peripheral venous blood samples according to
standard procedures. In total, 380 subjects from the GARP study
and 725 controls were genotyped by mass spectrometry (homo-
geneous MassARRAY system; Sequenom, San Diego, CA) using
standard conditions. PCR reactions were carried out in a ﬁnal vol-
ume of 5 ml and contained 2.5 ng of genomic DNA. Genotypes were
assigned using Genotyper version 3.0 software (Sequenom, San
Diego, CA). All SNPs were in HardyeWeinberg equilibrium.
Analysis strategy
Because hand OA is by far the most prevalent OA phenotype in
the GARP study, we choose to study hand OA. The other OA phe-
notypes were not studied. Radiographic progression of hand OA
was assessed after 2 and after 6 years, with only partly overlap.
These two groups may reﬂect subjects with different disease pro-
gression phenotypes, fast and more gradual progression. Since the
6-year cohort has the largest number of patients and due to the
longer follow-up period also the largest number of progressors, we
used this group for the initial analysis. This implicates that if there
is any association the chance of ﬁnding it in this group is higher
compared to the 2-year cohort. In this analysis we compared sub-
jects with OA progression over 6 years (cases) to the controls in
a cross-sectional approach to establish the association between the
SNPs with OA progression. We used this caseecontrol approach to
assess the risk of radiographic progression of hand OA for the SNPs
compared to the background risk of the general population. To
further explore SNPs showing evidence for association in this initial
analysis, we repeated the caseecontrol analysis in the 2-year cohort
for these SNPs. In addition we used a quantitative approach within
the hand OA patients in both cohorts comparing mean change in
osteophytes and JSN scores across the SNP genotypes showing
evidence for association in the initial analysis. The change in
osteophyte and JSN scores was calculated by subtracting the
baseline score from the follow-up score for each of these features.
Statistical analysis
In our 6-year cohort the statistical power given a minor allele
frequency (MAF) of 0.37 using a log additive model with a ¼ 0.05
was 81% to detect an odds ratio (OR) of 1.55 or higher (Quanto
software version 1.2.4 (University of Southern California, USA;
http://hydra.usc.edu/gxe)).
Associations were analysed using SPSS, version 16.0 (SPSS Inc.,
Chicago, IL). In the initial analysis (6-year cohort) we assessed the
association between the three SNPs and the presence of radio-
graphic progression as well as hand OA susceptibility in a casee
control comparison. Allelic ORs were estimated by comparing the
number of alleles among cases and controls using Generalized
Estimating Equations models with robust variance estimators to
account for familial dependency among sibling pair and sex was
added as covariate.
The SNPs showing evidence for association were subsequently
assessed in the 2-year cohort using the same caseecontrol com-
parison. For these SNPs we also used a quantitative approach
within the hand OA patients comparing the mean change in
Table I
Baseline characteristics of patients with radiographic hand OA in the 6-year cohort
and the 2-year cohort
6-Year cohort
(N ¼ 161)
2-Year cohort
(N ¼ 128)
Age, yrs, mean (SD) 60.0 (7.2) 61.0 (6.7)
Women, no (%) 131 (81) 105 (82)
Postmenopausal women, no (%) 124 (95) 100 (95)
Body mass index, kg/m2, mean (SD) 27.2 (5.0) 26.2 (3.3)
Symptomatic hand OA, no (%) 131 (81) 103 (80)
Additional ROA sites, no (%)
Knee 72 (45) 67 (52)
Hip 43 (27) 49 (38)
Facet OA 107 (66) 90 (70)
Spine degenerative disc 112 (69) 101 (79)
Abbreviation: ROA: radiographic OA.
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baseline score) across SNP genotypes using linear mixed models.
Adjustment was made for age, sex, BMI and a random intercept was
included to adjust for family effects within sibling pairs.
Results
Study population
Of the 384 patients in the GARP study, 251 fulﬁlled the deﬁnition
of radiographic hand OA and were included in the present study.
Radiographic follow-up data over 6 years were available in 161
patients (64%). In 128 patients (51%) radiographic follow-up data
over 2 years were available. Data over both periods were present in
86 patients meaning that these patients are represented in the
6-year and in the 2-year cohort.
Baseline characteristics are shown in Table I. Since patients in
the 2-year follow-up study were selected based on the presence of
knee or hip OA, the prevalence of these OA phenotypes was higher
in this population. In controls the mean age (SD) was 58.8 years
(7.4) and 58% were female.
In the 6-year cohort 97 (60%) patients had radiographic pro-
gression of hand OA. Progression of osteophytes and JSN was pre-
sent in 85 (53%) and 52 (32%) patients, respectively. Over 2 years
radiographic progressionwas present in 50 (39%) hand OA patients.
Osteophyte and JSN progression was present in 31 (24%) and 37
(29%) patients, respectively.Table II
Association between three SNPs within ASPN, BMP5 and GDF5 and the presence of hand
distributions, minor allele frequencies (MAF) and the total number of alleles (n) for the var
hand OA patients with radiographic progression of hand OA over 6 years
TT CT CC
ASPN rs13301537
Controls 366 297 62
Presence hand ROA 119 104 26
Radiographic progression 37 47 12
BMP5 rs373444
Controls 271 334 104
Presence hand ROA 82 113 44
Radiographic progression 33 45 14
CC CT TT
GDF5 rs143383
Controls 105 330 290
Presence hand ROA 31 131 86
Radiographic progression 14 44 38
Abbreviation: ROA: radiographic OA.
* Adjusted for family effects within sibling pairs and sex.Genetic association with hand OA progression over 6 years
In Table II results of the initial analysis comprising the casee
control comparison in the 6-year cohort are shown. MAF and
genotype distributions are provided for the ASPN, BMP5 and GDF5
variants in controls, all patients with radiographic hand OA
(N¼ 251) at baseline and patients with progression of hand OA over
6 years (N ¼ 97). MAF was similar between controls and patients
with radiographic hand OA. The minor allele of the SNP rs13301537
in ASPN was associated with hand OA progression with an OR (95%
CI) of 1.49 (1.06e2.07) and a nominal P-value of 0.020. After
adjustment for multiple testing (N ¼ 3) this association had
suggestive evidence for association with radiographic progression
(P ¼ 0.06). To further investigate this effect we stratiﬁed the
analysis for progression of osteophytes and progression of JSN.
This showed consistent allelic association with the ASPN SNP
rs13301537 with an OR (95% CI) of 1.53 (1.07e2.11) for
osteophytes (P ¼ 0.019) and an OR (95% CI) of 1.70 (1.14e2.55) for
JSN (P ¼ 0.010).
Themean change in osteophytes and JSN scores across ASPN SNP
rs13301537 genotypes was higher in homozygous and heterozy-
gous carriers of the minor allele compared to homozygous carriers
of the common allele (Table III), with a mean difference in change
score of 0.73 (95% CI e 0.07e1.56; P ¼ 0.073) for osteophytes and
0.82 (95% CI 0.12e1.52; P ¼ 0.022) for JSN. There was no dose
response effect of the allele.
Association of ASPN SNP rs13301537 with hand OA progression over
2 years
Subsequently ASPN SNP rs13301537 was assessed in the 2-year
cohort showing a similar effect size for the association with hand
OA progression over that period compared to the 6-year cohort
(Table IV). However, only the association for progression of osteo-
phytes reached nominal statistical signiﬁcance.
The mean change in osteophyte and JSN score was considerably
higher in homozygous carriers of the minor allele of the ASPN SNP
rs13301537 compared to the other genotypes (Table V), with
a mean difference in change score of 1.10 (95% CI 0.24e1.96;
P ¼ 0.012) for osteophytes and 0.91 (95% CI 0.10e1.72; P ¼ 0.028)
for JSN.
Because the ASPN SNP rs13301537 has shown to be in linkage
disequilibriumwith the frequently described D14 and D13 alleles inOA as well as the progression of hand OA over 6 years expressed as OR. Genotype
iants are provided in controls, all patients with radiographic hand OA at baseline and
MAF n Allelic OR (95% CI)* P-value
0.29 1418
0.32 489 1.15 (0.88e1.49) 0.309
0.37 189 1.49 (1.06e2.07) 0.020
0.38 1388
0.42 469 1.12 (0.87e1.43) 0.375
0.40 181 0.99 (0.72e1.37) 0.954
MAF n Allelic OR (95% CI)* P-value
0.37 1418
0.39 487 0.98 (0.78e1.23) 0.859
0.37 189 1.04 (0.72e1.51) 0.833
Table III
Mean change (SD) in osteophytes and JSN in the hand over 6 years for ASPN SNP
rs13301537 genotypes
TT (N ¼ 67) CT (N ¼ 73) CC (N ¼ 19)
Change osteophytes, mean (SD) 1.8 (2.2) 2.5 (2.8) 2.7 (3.0)
Change JSN, mean (SD) 1.0 (1.7) 1.8 (2.6) 1.7 (1.8)
Table V
Mean change (SD) in osteophytes and JSN over 2 years for ASPN SNP rs13301537
genotypes
TT (N ¼ 59) CT (N ¼ 58) CC (N ¼ 10)
Change osteophytes, mean (SD) 0.4 (1.0) 0.6 (1.1) 1.5 (3.0)
Change JSN, mean (SD) 0.4 (1.2) 0.4 (1.1) 1.3 (2.0)
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involving a second ASPN SNP rs331377, to assess whether the effect
is attributable to these D-repeat polymorphisms. We found that the
D14 and D13 alleles were not associated with progression of hand
OA over both periods, suggesting that the effect of the ASPN SNP
rs13301537 independent of D14 and D13.
Discussion
In this study we investigated whether SNPs within ASPN, BMP5
and GDF5 are related to the progression of hand OA over 6 years in
participants of the GARP study. Subsequently, SNPs with suggestive
evidence for association were investigated for association with
hand OA progression over 2 years, reﬂecting fast progression. We
found that the SNP rs13301537 in ASPN was associated with
radiographic progression of hand OA over 6 years (P ¼ 0.020). The
minor allele of this variant was more common in patients with
progression of hand OA compared to healthy controls. In addition,
the mean change in osteophytes and JSN was higher in C-allele
carriers compared to the TT genotype. In the 2-year cohort similar
effect sizes were found, with the mean change in osteophytes and
JSN being signiﬁcantly higher in homozygous C-allele carriers. In
patients with progression over both time periods (N ¼ 25), effect
sizes for ASPN were similar to the risk in the whole 6-year and 2-
year cohort implying that the effects over the long term and short
term are independent.
This study is the ﬁrst to assess speciﬁc genes associated with
hand OA progression. To our knowledge there is only one other
study investigating the association between speciﬁc SNPs and OA
progression, which concerned knee OA20. One of the reasons for the
lack of genetic association studies on OA progression is the lack of
follow-up data in combinationwith genotype data, especially when
the hand is concerned. It is of interest to assess OA progression
because this phenotype is clinically most relevant with respect to
development of new interventions and patient management.
The ASPN SNP we found to be associated with hand OA pro-
gression was originally identiﬁed by Kizawa et al. as susceptibility
gene for both knee and hip OA in two independent Asian pop-
ulations10. Apart from the genetic association they demonstrated
that ASPN is abundantly expressed in articular cartilage and inhibits
expression of genes encoding aggrecan and type II collagen. Our
association for ASPN SNP rs13301537 with OA progression was in-
dependent from the D14 and D13 alleles in the D-repeat poly-
morphisms, although these SNPs are in linkage disequilibrium. InTable IV
Association between ASPN SNP rs13301537 and progression of hand OA over 2 years
expressed as OR. Genotype distributions, minor allele frequencies (MAF) and the
total number of alleles (n) are provided in controls and hand OA patients with
radiographic progression of hand OA over 2 years
TT CT CC MAF n Allelic OR (95% CI)* P-value
Controls 366 297 62 0.29 1418
Radiographic
progression
19 25 6 0.37 99 1.48 (0.95e2.32) 0.087
Progression
osteophytes
10 16 5 0.43 61 1.85 (1.08e3.18) 0.025
Progression JSN 14 18 5 0.38 73 1.55 (0.92e2.60) 0.102
* Adjusted for family effects within sibling pairs and sex.the studies of Kizawa et al., D14 allele in the ASPN D-repeat poly-
morphism was found to increase OA risk, the D13 allele was pro-
tective. In a Greek population the association between the D-repeat
polymorphisms was conﬁrmed for knee OA21. In Spanish and
British populations no relationship with knee or hip OA was
observed22,23. A study on the relationship between various
ASPN polymorphisms and hand OA susceptibility showed no
association24.
ASPN inhibits both early- and late-stage chondrogenesis trough
suppression of TGF-b, a central player among growth factors in
articular cartilage10,12. Excessive ASPN activity reduces TGF-b func-
tion to less optimal levels, leading to cartilage degeneration. Our
ﬁndings suggest that this imbalance between ASPN and TGF-b is an
ongoing process leading not only to the development, as shown in
earlier research, but also to progression of OA. This was evident for
long-term progression and probably also for progression on the
short term. This interaction between ASPN and TGF-b, leading to
suboptimal TGF-b levels is a potential target for therapeutic
approaches.
We did not ﬁnd an association between hand OA presence at
baseline and the ASPN SNP. An explanation is that the SNP is
associated with a subset of more progressive hand OA. The whole
group comprises a wide variety of hand OA types, both slow and
faster progressive types. Therefore analysis in thewhole group does
not show a relationship with the SNP.
There are a number of potential limitations to be addressed.
Although it is generally known that small studies are subject to
spurious results and need replication to assess robust effects, we did
not replicate our results. This is mainly due to a lack of populations
with both radiographic follow-up data on hand OA and genotype
data, implying that replication of our data was not possible at this
time. Furthermore, our sample sizewas relatively smallwhen genetic
research is considered. For this reason we used a candidate gene
approach with carefully selected SNPs within one pathway shown to
be consistently associated with OA susceptibility. As mentioned
above our population is unique because both radiographic follow-up
data on hand OA and genotype datawere availablewhich gave us the
opportunity to assess the inﬂuence of these SNPs on hand OA pro-
gression. Taking these issues together, this study should be appre-
ciated as an initial result for further research on the role of speciﬁc
polymorphisms in OA progression. Despite these limitations we
found an association between hand OA progression and ASPN over
both follow-up periods. As discussed above, these effects seem in-
dependent, increasing the credibility of the association.
In conclusion, we found that ASPN SNP rs13301537 was asso-
ciated with progression of hand OA over both 6 and 2 years. This
ﬁnding gives insight in the pathogenesis of hand OA progression
and identiﬁed a potential target for the development of therapeutic
approaches.
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